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To test the effectiveness of mid-regional pro-adrenomedullin (MR-proADM) in comparison
to C-reactive protein (CRP), procalcitonin (PCT), D-dimer, lactate dehydrogenase (LDH) in
predicting mortality in COVID-19-ICU-patients.
Methods
All consecutive COVID-19 adult patients admitted between March and June 2020 to the ICU
of a referral, university hospital in Northern-Italy were enrolled. MR-proADM and routine lab-
oratory test were measured within 48 hours from ICU admission, on day 3, 7 and 14. Sur-
vival curves difference with MR-proADM cut-off set to 1.8 nmol/L were tested using log-rank
test. Predictive ability was compared using area under the curve and 95% confidence inter-
val of different receiver-operating characteristics curves.
Results
57 patients were enrolled. ICU and overall mortality were 54.4%. At admission, lymphocytope-
nia was present in 86% of patients; increased D-dimer and CRP levels were found in 84.2%
and 87.7% of patients respectively, while PCT values > 0.5 μg/L were observed in 47.4% of
patients. MR-proADM, CRP and LDH were significantly different between surviving and non-
surviving patients and over time, while PCT, D-dimer and NT-pro-BNP did not show any differ-
ence between the groups and over time; lymphocytes were different between surviving and
non-surviving patients only. MR-proADM was higher in dying patients (2.65±2.33vs1.18±0.47,
p<0.001) and a higher mortality characterized patients with MR-proADM >1.8 nmol/L (p =
0.016). The logistic regression model adjusted for age, gender, cardiovascular disease, diabe-
tes mellitus and PCT values confirmed an odds ratio = 10.3 [95%CI:1.9–53.6] (p = 0.006) for
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MR-proADM >1.8 nmol/L and = 22.2 [95%CI:1.6–316.9] (p = 0.022) for cardiovascular dis-
ease. Overall, MR-proADM had the best predictive ability (AUC = 0.85 [95%CI:0.78–0.90]).
Conclusions
In COVID-19 ICU-patients, MR-proADM seems to have constantly higher values in non-sur-
vivor patients and predict mortality more precisely than other biomarkers. Repeated MR-
proADM measurement may support a rapid and effective decision-making. Further studies
are needed to better explain the mechanisms responsible of the increase in MR-proADM in
COVID-19 patients.
Introduction
From December 2019, when the coronavirus disease (COVID-19) first emerged in Wuhan
(China), a total of over 19 million COVID-19 cases and 720,000 deaths have been reported
globally [1]. Unfortunately, multiple aspects of the disease, especially regarding identification
criteria and early Intensive Care management [2], remain unclear.
As in any context of urgency, finding a biomarker able to identify more severe cases is an
objective either desired or difficult to achieve. In COVID-19 pandemic, multiple indicators
were able to highlight increased severity, especially if combined together [3], but none have
been proved entirely effective.
Since the virus-induced endothelial dysfunction is a possible contributing factor to the evo-
lution of COVID-19 infection [4], the need to evaluate the role of Adrenomedullin (ADM) has
been recently highlighted [5]. ADM is a multipotent regulatory peptide with a number of bio-
logical activities—vasodilator, positive inotropic, diuretic, natriuretic and bronchodilator—
widely expressed throughout the body, including bone, adrenal cortex, kidney, lung, blood
vessels and heart. It is upregulated by hypoxia, inflammatory cytokines, bacterial products and
shear stress [6]. ADM is even present in pulmonary pneumocytes type 2, smooth muscle cells,
neurons and immune cells [7], making it a promising molecule to investigate in relation to
ARDS, as realized after cardiac surgery [8].
Due to the fact that ADM measurement is known to be complicated, mid-regional pro-
adrenomedullin (MR-proADM) has been proposed as an estimate of ADM [9]. High levels of
MR-proADM has been reported in septic patients and particularly its specific prognostic value
has been described not only for early diagnosis in the context of Emergency Department (ED),
but also for risk stratification and prognosis prediction in Intensive Care Units (ICU) [10–13].
MR-proADM has been hypothesizes to have a role either to identify bacterial infections in
ICU patients or to select patient to dismiss towards lower-intensity care wards [14–16].
In the context of severe acute respiratory insufficiency characterizing COVID-19 patients
admitted to intensive care units (ICU), we compared the effectiveness of MR-proADM to
describe patient’s severity and to predict the mortality with other biomarkers commonly used
in sepsis and pneumonia.
Methods
Study design and population
It is an observational, prospective, single-centre study conducted between March and June
2020 at the “Città della Salute e della Scienza” University Hospital (Turin, Northern Italy) in
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the regional referral ICU for the treatment of severe respiratory failure and Extracorporeal
Membrane Oxygenation (ECMO) support in combination with two new temporary ICUs cre-
ated to face the COVID-19 pandemic. The study protocol was approved by the local Ethics
Committee and was performed in accordance with the principles set put in the Declaration of
Helsinki. The data collection was performed anonymously and the need for consent was
waived by the Local Ethics Committee.
All consecutive adult patients requiring ICU admission expected to last longer than 48
hours and suffering from pneumonia by Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2), confirmed by the real-time polymerase-chain-reaction (RT-PCR) on at least
one low respiratory tract specimen [17] were enrolled.
All patients were treated according to internal protocols for the management of patients
with severe respiratory insufficiency in combination with the new directions emerged from
the recent literature about COVID-19 pneumonia [18, 19].
Patients’ monitoring: Laboratory exams and imaging
At ICU admission, all patients underwent the assessment of clinical and routine laboratory tests
in addition to C-reactive protein (CPR), procalcitonin (PCT), D-dimer, lactate dehydrogenase
(LDH), N-terminal prohormone brain natriuretic peptide (NT-pro-BNP), performed according
to the methods currently used in our laboratory. These specific exams were repeated at day 3
(after 72 hours), 7 and 14. MR-proADM was measured (see below) during patients’ ICU stay
(within 48 hours of from ICU admission), after 72 hours (day 3) and on days 7 and 14.
The Chest X-rays or CT-scans and microbiological cultures of blood, sputum, bronchial
aspirate or bronchoalveolar samples were performed based on the intensivist’s judgment to
assess the progression of the disease.
MR-proADM analysis
A sample of blood from an EDTA-containing tube was centrifugated at 4000 rpm for five min-
utes and then a plasma aliquot was immediately frozen and stored at –80˚C. When sufficient
samples were collected to complete the capacity of the instrument, the MR-proADM measures
were determined by the B.R.A.H.M.S. KRYPTOR compact PLUS (Thermo Fisher Scientific,
Hennigsdorf, Germany) automated method using the TRACE (Time-Resolved Amplified
Cryptate Emission) technique. The detection limit of the assay was 0.05 nmol/L, while intra-
and inter-assay coefficients of variation were under 4% and 11%, respectively.
Data collection
Patient’s demographic characteristics, clinical history, length of mechanical ventilation and
ECMO support, if used, were collected from medical records. Ventilatory free-days (VFDs)
were defined as: VFDs = 0, if subject died within 28 days of mechanical ventilation or if the
subject was mechanically ventilated for more than 28 days; VFDs = 28 − x, if the patient was
weaned from ventilation “x” days after its start [20].
All the episodes of ventilator associated pneumonia (VAP) and/or blood stream infection
(BSI), except for the SARS-CoV-2 infection, as well as the requirement of vasoactive drugs
with the development of septic shock [21], were registered according to the European Centre
for Disease Prevention and Control (ECDC) current definitions [22].
Off-label use of anti-inflammatory treatments for COVID-19 (i.e. steroid treatment with
intravenous methylprednisolone at any dosage and/or intravenous tocilizumab at 8 mg/kg
repeated once) were recorded if administered (yes or not).
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All patients were followed-up until the hospital discharge to compute: ICU, 28-day and
overall mortality, length of ICU and hospital stay.
Statistical analyses
Summary data were presented as means and standard deviations or median and interquartile
range for continuous variables and as percentages for categorical variables. In univariate analy-
sis, continuous variables were compared using the unpaired t test or Wilcoxon-Mann-Whit-
ney according to distribution type. Categorical variables were compared using Fisher exact test
or the Chi-square test, as appropriate.
For survival analysis we used Kaplan Meier method considering a period of 28 days. Log-
rank test was used to assess the differences between survival curves considering the MR-
proADM cut-off of 1.8 nmol/L reported in community-acquired pneumonia studies either in
ED or ICU [23–26].
To control potential confounding effects a logistic regression model adjusted for age, gen-
der, cardiovascular disease, diabetes mellitus and PCT values at baseline was used. Results are
presented as Odds Ratio (OR) and confidence interval (CI) at 95% level.
To analyze the time course of biomarkers profiles in the different patient groups, a general-
ize linear model for repeated measures was used.
Predictive ability of MR-proADM, PCT, CRP, NT-proBNP, LDH and D-dimer to discrimi-
nate surviving patients was compared using area under the curve (AUC) and 95% confidence
interval (CI) of different receiver-operating characteristics curves (ROC) using DeLong’s test.
All tests were two sided and the level of statistical significance was set at 0.05.
All the analyses were performed with the open-source R (R 3.5.0) and SAS software, version
9.4 (SAS Institute Inc., Cary, NC).
Results
In the period March 1st—April 30th, 2020, 57 patients, whose demographic and clinical charac-
teristics are summarized in Table 1, were enrolled. At arrival in our ICU, 38 (66.7%) patients
required mechanical ventilation, 9 (15.8%) underwent veno-venous Extracorporeal Membrane
Oxygenation (vv-ECMO) and 13 (22.8%) were already affected by a major bacterial super-
infection. The Sequential Organ Failure Assessment (SOFA) score at admission in our ICU
was 7 (IQR 4–10), median between survivor and non-survivor 4 (IQR 3–7) and 9 (IQR 6–12)
respectively (p value 0.002). Thirty-one (54.4%) patients developed new bacterial co-infections
within 21 days in ICU, presented as VAP, BSI or VAP combined with BSI (38.6%, 36.8% and
22.8%, respectively). Septic shock occurred in 33.3% of patients.
ICU and overall mortality were 54.4% (no patient died after ICU discharge); 22 (38.6%)
patients were discharged to medical wards while four patients were still in ICU on June 30th,
2020. Median ICU and hospital length of stay were 15 and 24 days, respectively. The incidence
of superinfection and septic shock were lower in survivors (p-value 0.027 and 0.011, respec-
tively) (Table 1).
Within the first 24 hours, lymphocytopenia (defined as lymphocytes <1.50 × 109/L) was
present in 86% of patients and was severe (lymphocytes <1.0 × 109/L) in 56.1%; increased D-
dimer (defined as> 500 μg/L) and CRP levels (> 10 mg/L) were found in 84.2% and 87.7% of
patients respectively, while PCT values higher than 0.5 μg/L were observed in 47.4% (Table 2).
MR-proADM, CRP and LDH were significantly different between surviving and non-sur-
viving patients and over time, while PCT, D-dimer and NT-pro-BNP did not show any differ-
ence between the groups and over time; the lymphocytes count was different between
surviving and non-surviving patients only (Fig 1).
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MR-proADM value at 48 hours from ICU admission (defined as “predictive value”) was
significantly higher in dying patients (2.65±2.33vs1.18±0.47, p-value <0.001) and a higher
mortality characterized patients presenting a predictive value of MR-proADM exceeding the
cut-off of 1.8 nmol/L (p value 0.016) (Fig 2).
Table 1. Clinical characteristics and outcomes.
Clinical characteristics Overall N = 57 Survivors N = 26 Non-survivors N = 31 p value
Age, years, median (IQR) 64 (54–71) 59 (53–67) 67 (56–74) 0.040
Gender, male, n (%) 50 (87.7) 22 (84.6) 28 (90.3) 0.513
Patients transferred from other ICUs, n (%) 34 (59.6) 15 (57.7) 19 (61.3) 0.783
Patients with underlying comorbidities, n (%) 44 (77.2) 18 (69.2) 26 (83.9) 0.189
Obesity, n (%) 25 (43.9) 11 (42.3) 14 (45.2) 0.829
Hypertension, n (%) 31 (54.4) 13 (50.0) 18 (58.1) 0.543
Cardiovascular disease, n (%) 11 (19.3) 1 (3.8) 10 (32.3) 0.008
Chronic lung disease, n (%) 2 (3.5) 2 (7.7) 4 (12.9) 1.000
Acute smoker, n (%) 6 (10.5) 3 (11.5) 3 (9.7) 1.000
Diabetes mellitus, n (%) 11 (19.3) 2 (7.7) 9 (29.0) 0.051
Invasive mechanical ventilation at arrival, n (%) 38 (66.7) 15 (57.7) 23 (74.2) 0.188
ECMO at arrival, n (%) 9 (15.8) 4 (15.4) 5 (16.1) 1.000
Superinfection at arrival, n (%) 13 (22.8) 3 (11.5) 10 (32.3) 0.111
Steroids, n (%) 21 (36.8) 8 (30.8) 13 (41.9) 0.474
Tocilizumab, n (%) 26 (45.6) 15 (57.7) 11 (35.5) 0.094
Outcomes Overall N = 57 Survivors N = 26 Non-Survivors N = 31 p value
28-day mortality, n (%) 27 (47.4)
Overall mortality, n (%) 31 (54.4)
VFDs at day 28 in ICU, median (IQR) 4 (0–2) 14 (0–20) 0 (0–0) < 0.001
ICU LOS, days, median (IQR) 15 (8–26) 9 (6–25) 20 (11–28) 0.054
Hospital LOS, days, median (IQR) 24 (17–32) 28 (20–35) 20 (12–30) 0.006
Superinfection within 21 days in ICU, n (%) 31 (54.4) 10 (38.5) 21 (67.7) 0.027
VAP, n (%) 22 (38.6) 6 (23.1) 16 (51.6) 0.028
BSI, n (%) 21 (36.8) 9 (34.6) 12 (38.7) 0.750
Septic shock, n (%) 19 (33.3) 4 (15.4) 15 (48.4) 0.011
List of abbreviations: IQR: interquartile range; ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation; VFDs: ventilatory free days; LOS: length of stay;
VAP: ventilatory acquired pneumoniae; BSI: blood stream infection.
https://doi.org/10.1371/journal.pone.0246771.t001
Table 2. Laboratory parameters at baseline.
Laboratory range Overall N = 57 Survivors N = 26 Non-Survivors N = 31 p value
WBC, cell x109/L 4.00–10.00 12.85 ± 7.88 10.14 ± 6.27 15.13 ± 8.44 0.016
Lymphocytes, cell x109/L 1.00–4.00 1.03 ± 1.11 1.27 ± 1.53 0.82 ± 0.47 0.690
D-dimer, ng/mL < 540 10872 ± 21561 10714 ± 24570 11001 ± 19209 0.895
LDH, UI/L 250–450 879 ± 345 749 ± 196 923 ± 295 0.007
NT-proBNP, pg/mL < 300 2988 ± 12102 514 ± 760 5153 ± 16407 0.009
PCT, μg/L <0.5 3.34 ± 8.15 1.37 ± 3.48 4.93 ± 10.30 0.050
CRP, mg/L < 5.0 131.8 ± 104.6 115.5 ± 105.3 145.5 ± 103.7 0.208
The parameters corresponded to the first available measures performed within 24 hours from ICU admission. Values are expressed as mean ± standard deviation (SD).
List of abbreviations: WBC: white blood cell; LDH: lactate dehydrogenase; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; PCT: procalcitonin; CRP:
C-reactive protein.
https://doi.org/10.1371/journal.pone.0246771.t002
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Fig 1. Trends of MR-proADM, CPR, PCT, LDH, D-dimer, lymphocytes and NT-proBNP from ICU admission
(day 0) to day 14 in survivor (white) and non-survivor (grey) patients. Time dependent analysis of MR-proADM,
CRP and LDH were significantly different between survivors and non-survivors (p-value<0.0001, 0.04 and 0.0253,
respectively) and over the time (p-value 0.0193, 0.0003 and 0.0095, respectively), while lymphocytes differed only
between survivors and non-survivors (p-value 0.0463). List of abbreviations: MR-proADM: mid-regional pro-
adrenomedullin; CRP: C-reactive protein; LDH: lactate dehydrogenase; PCT: procalcitonin; NT-proBNP: N-terminal
prohormone of brain natriuretic peptide.
https://doi.org/10.1371/journal.pone.0246771.g001
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This result was confirmed by the logistic regression model adjusted for age, gender, cardio-
vascular disease, diabetes mellitus and PCT values at baseline which confirmed a statistically
significant odds ratio equal to 10.3 [95%CI:1.9–53.6] (p = 0.006) for MR-proADM values
higher than 1.8 nmol/L and equal to 22.2 [95%CI:1.6–316.9] (p = 0.022) for cardiovascular dis-
ease (Table 3).
MR-proADM trend analysis in the subgroup of patients undergoing vv-ECMO evidenced a
statistically significant difference between surviving and non-surviving patients (p = 0.046) but
not over time (p = 0.205) (Fig 3).
Overall, MR-proADM was found to have the best predictive ability compared to other bio-
markers as shown in Fig 4 (AUC = 0.85 [95%CI:0.78–0.90]). The combination of different bio-
markers (MR-proADM+PCT: AUC = 0.85 [95%CI:0.79–0.90]; MR-proADM+CRP:
AUC = 0.84 [95%CI:0.78–0.89]) was unable to reach a better statistically significant result.
Discussion
The present prospective observational study evidenced that MR-proADM, measured within
48 hours from admission, was significantly higher in patients with worse outcome and that a
higher mortality characterized patients presenting a predictive value of MR-proADM exceed-
ing the cut-off of 1.8 nmol/L [23–26]. A result maintaining its statistical significance even in a
Fig 2. Kaplan-Meier survival curve. Stratification of patients with mid-regional pro-adrenomedullin (MR-proADM)
levels greater or less than 1.8 nmol/L at ICU admission.
https://doi.org/10.1371/journal.pone.0246771.g002
Table 3. Multivariate logistic regression analysis for mortality.
Odds Ratio 95% CI p value
Age 1.004 0.932–1.083 0.9121
Gender, male 3.020 0.390–23.393 0.2899
Cardiovascular disease 22.206 1.556–316.960 0.0223
Diabetes mellitus 7.481 0.964–58.062 0.0543
PCT values at baseline 1.113 0.945–1.312 0.1998
MR-proADM >1.8 nmol/L 10.274 1.970–53.578 0.0057
List of abbreviations: CI: confidence interval; PCT: procalcitonin; MR-proADM: mid-regional pro-adrenomedullin.
https://doi.org/10.1371/journal.pone.0246771.t003
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multivariate logistic regression model including age, gender, cardiovascular disease, diabetes
mellitus and PCT values at admission as possible confounding. Moreover, its ability to
Fig 3. Trends of mid-regional pro-adrenomedullin (MR-proADM) from ICU admission (day 0) to day 14 in
survivor (white) and non-survivor (grey) patients who required VV-ECMO. Time dependent analysis of MR-
proADM was significantly different between survivors and non-survivors (p-value 0.042) but it was not over the time
(p-value 0.205).
https://doi.org/10.1371/journal.pone.0246771.g003
Fig 4. ROC curves of MR-proADM, PCT, CRP, NT-proBNP, LDH and D-dimer and their comparison for
predicting mortality. List of abbreviations: MR-proADM: mid-regional pro-adrenomedullin; PCT: procalcitonin;
CRP: C-reactive protein; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; LDH: lactate
dehydrogenase; AUC: area under the curve; CI: confidence interval.
https://doi.org/10.1371/journal.pone.0246771.g004
PLOS ONE Effectiveness of mid-regional pro-adrenomedullin as prognostic marker in COVID-19 critically ill patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0246771 February 8, 2021 8 / 14
discriminate surviving patients was found to be better than all other biomarkers usually mea-
sured in ICU.
Finding a biomarker able to identify patients with worst outcome has always been a chal-
lenge, especially in ICU, but emerged as a priority in the context of the pandemic induced by
COVID-19 leading even the most advanced health systems to face the problem of the limited
health resources available.
MR-proADM appears to be a biomarker with a strong prognostic value. This finding is
even supported by a series of experimental evidences attributing to ADM a major role in the
regulation of vascular permeability and endothelial barrier [27], on inflammation mediators
and microcirculation [28]. All mechanisms certainly playing a role in the development of
organ failures characterizing the pathology induced by SARS-CoV2.
To the best of our knowledge, none previously compared sequential measurements of con-
ventional biomarkers such as PCT, C-RP, and other laboratory tests such as lymphocytes, NT-
pro-BNP, LDH with MR-proADM values in a cohort of COVID-19 critically ill patients
admitted in ICU.
The choice to study the progress of some biomarkers already in use in clinical practice in
our patients was taken in accordance with the evidences from the existing literature at the
beginning of the pandemic. It is in fact known that a number of laboratory parameters are
altered in COVID-19 patients and that some of these alterations, such as the decrease in lym-
phocyte count [29] and increase in LDH, D-dimer, CRP [30, 31] could be considered predic-
tors of adverse clinical outcomes.
In the population we studied, we observed lymphopenia and an increase in CRP and LDH.
NT-proBNP showed a high value at baseline, not confirmed by the values of the trend over
time.
Although serum procalcitonin levels are generally normal in patients with viral infections,
we observed that these increased in about half of our cases and continued to remain higher
than normal during ICU stay. It is reasonable that this increase reflects the occurrence of bac-
terial superinfection possibly contributing to unfavorable outcomes [32].
MR-proADM ROC analysis showed that this biomarker has significantly greater prediction
skill. It is therefore reasonable to hypothesize that MR-proADM is the best biomarker to pre-
dict outcome of patients either at admission or during ICU stay. It follows that, as found in
sepsis and septic shock [10, 16], the inclusion of MR-proADM monitoring into an early clini-
cal management protocol may support diagnostic intervention and facilitate the choice of the
most appropriate treatment in case of organ dysfunctions.
The rise of MR-proADM, resulting from a dose-response mechanism induced by the host-
pathogen interaction, appears to occur in the initial phase of pathogen recognition which
means, in the case of COVID-19, at the time of hospital admission or even before. However, it
is interesting to note that the increase tends to persist over the days in line with the persistence
of the disease, underlying the additional value of this biomarker in predicting patient’s out-
come. Low values, on the other hand, seems to characterize patients with a shorter ICU length
of stay and a lower mortality. It follows that MR-proADM could even be an interesting bio-
marker to monitor the disease progression even if this is outside from the objectives of the
present study.
So far, a predictive value of individual MR-proADM measurements has been found in
ischemic and congestive heart disease [33, 34], after cardiac surgery [8], in sepsis [35], in pneu-
moniae [13, 36] and in other ARDS-related conditions [37]. Despite the low number of cases
affected by serious viral pathologies included in previous studies [14, 38], we believe that a sim-
ilar effect can be hypothesized in the context of cohorts of COVID-19 patients. It is hence pos-
sible, as already proposed in the context of sepsis [16], that the use of this biomarker could
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help either to anticipate the escalation of therapy in patients at risk of treatment failure or to
suggest a faster discharge of patients with a low risk of unfavorable evolution.
Particularly interesting is the observation that MR-proADM trend, in our small subpopula-
tion of patients treated with ECMO, is significantly different between surviving and non-sur-
viving patients. This in spite of the typical inflammatory response proved to be associated with
the use of extracorporeal circulation [39]. This observation certainly deserves further investiga-
tion in larger cohorts of patients treated with extracorporeal circulation and monitored by
MR-proADM.
A further aspect to discuss regards the identification of an appropriate cut-off of MR-
proADM. Although Krintus et al. reported normality values ranging between 0.21 (0.19–0.23)
and 0.57 nmol/L [9], the literature is not univocal in defining a single pathological cut-off.
There are evidences, mainly related to sepsis, septic shock, and community-acquired pneumo-
nia (CAP) proposing values ranging between 0.9 and 5.19 nmol/L [36, 40] or more. Consider-
ing COVID 19 as a severe community pneumonia, we chose the cut-off 1.8 nmol/L, suggested
by important studies on pneumonia [23–26]. The same cut-off is suggested concerning the
role of MR-proADM in predicting mortality in patients with sepsis or septic shock [41–43]. Of
course, the complexity of this new and only partially known infection makes it difficult to clas-
sify, and probably different values (as proposed in the context of septic shock or multi-organ
failure) could be adequate, considering that the cut-off may change accordingly to the outcome
investigated [13].
We included a population with clinical characteristics that are comparable with others Ital-
ian experience [19, 44]: a high proportion required mechanical ventilation at ICU admission
(66.7%); a median age of 64 years, with a high preponderance of the male sex (87.7%), and at
least one comorbidity in the 77.2%. Cardiovascular disease (other than hypertension) repre-
sented the most important comorbidity, with a statistically significant impact on outcome (p
value 0.008) even confirmed by the multivariate analysis (OR: 22.2 [IC:1.6–316.9]). This in line
with a large-scale study reporting that cardiovascular disease was a major risk factor for fatality
of COVID-19 patients [45].
We even observed that 22.8% of our patients presented superinfection at arrival and 54.4%
within 21 days in ICU. This aspect deserves particular attention. Bacterial and fungal infections
are in fact common complications of viral pneumonia, especially in critically ill patients.
Therefore, even among a wide number of articles reporting on COVID-19 clinical data, only a
few have reported secondary infection, mostly without detailed pathogens. Some reported a
low proportion of superinfections in hospitalized patients (7–8%) that rose to 14% in ICU, less
than in previous influenza pandemics [46]. Others reported that secondary infections were
identified in 5%-44% of ICU patients with COVID-19, being bacterial or fungal pneumonia
and bloodstream the most frequent infections [47], as in our cohort (VAP 38.6% and BSI
36.8%), where the total number of superinfections is higher overall. Interestingly, we found
that 33.3% of our patients developed septic shock due to superinfections. These data appear
more representative of a population of critically ill patients, with the need for invasive support,
prolonged hospitalization, and subjected to repeated, broad-spectrum antibiotic therapies.
Concerning mortality, our data are slightly higher than the values reported in the literature
(54.4%). In fact, in a recent metanalysis on 24 observational studies, in patients with completed
ICU admissions with COVID-19 infection, combined ICU mortality (95%CI) was 41.6%
(34.0–49.7%) [48]. To note, the in-ICU mortality from COVID-19 is far higher than usually
seen in ICU admissions with other viral pneumonias. Importantly, the mortality from com-
pleted episodes of ICU differs considerably from the crude mortality rates in some early
reports. For instance, in the Lombardy experience, ICU mortality was 26% as of March 25,
2020 [44] but rose to 48.7% in ICU and 53.4% in hospital as of May 30, 2020 [19]. It is
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undoubtedly true that our population had particularly severity conditions at admission, as
confirmed by the high percentage of patients transferred from other hospitals (59.6%); of
patients undergoing VV-ECMO (15.8%) or suffering from superinfection (54.4%) and septic
shock (33.3%).
Limits
Our study has some limits including a small sample size and a different ICU admission times
explained by the fact that our hospital, as a regional reference center, received particularly seri-
ous patients as secondary admission. Furthermore, no severity scores other than SOFA are
available as the context of the pandemic made data collection particularly difficult. Again, due
to the emergency context, it was not possible to have a comparison population and therefore
our cohort mainly includes mechanically ventilated patients. Finally, the role of possible
impact of confounding factors such as bacterial superinfections, cardiovascular disfunction
and renal failure cannot be clearly defined in this first cohort of patients.
Conclusions
MR-proADM is a new biomarker that seems to be able to effectively measure endothelial dam-
age. Its increased plasma levels indicate severity and worse prognosis in CAP, sepsis, ARDS,
perioperative care. The results of this study seem to suggest that, even in the context of the
COVID-19 pandemic, MR-proADM have constantly higher values in dying patients and
seems able to predict mortality better than other biomarkers. Repeated MR-proADM mea-
surement may hence support a rapid and effective decision-making.
Given that many aspects of COVID-19-induced disease are still unclear, we believe that fur-
ther studies are needed to better explain the mechanisms involved in the increase in MR-
proADM in patients with SARS-CoV-2 and in particular its relationship with multi-organ fail-
ure and superinfections.
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